Trevi Therapeutics, Inc. (TRVI)

The company is built around a single bet: that nalbuphine — a kappa agonist and mu antagonist that has been used clinically for decades as a pain reliever — can be reformulated as an extended-release oral drug that suppresses chronic cough without the abuse potential of traditional opioids. Idiopathic pulmonary fibrosis (IPF) kills lung tissue over time and triggers a relentless, unproductive cough that robs patients of sleep and quality of life. Existing treatments address the underlying disease progression but do nothing for the cough itself. Patients and physicians have almost no good options. That unmet need is Trevi’s opening.

The clinical argument

In a Phase 2b trial called CORAL, Haduvio showed placebo-adjusted reductions in 24-hour cough frequency of roughly 48 to 60 percent across dose groups at Week 6. Patients also reported improvements in cough-related nighttime awakenings and sleep. This is not a home run — a 48–60 percent reduction means the cough is still there, just less disruptive — but in an indication where the baseline is severe and no approved cough suppressant exists, it looks like something. The safety profile was consistent with prior studies: no unexpected serious adverse events, which matters given the company’s chief concern was whether extending nalbuphine dosing would surface side effects.

In refractory chronic cough — a broader label that includes patients with resistant cough not tied to a specific disease — the Phase 2a RIVER trial showed a 57 percent placebo-adjusted reduction in 24-hour cough frequency with strong responder rates and, again, a clean safety profile. These data are the company’s anchor. When Trevi sits down with the FDA, it brings CORAL and RIVER results to say: “This works. We know how to dose it. We know the side-effect profile.”

The FDA End-of-Phase 2 meeting affirmed that Trevi’s development plan is aligned with what the agency expects to see: two pivotal Phase 3 trials to confirm efficacy and safety, plus a handful of Phase 1 studies to satisfy pharmacology and drug-interaction questions. Phase 3 trials are expensive and take years. But Trevi has a glide path, not a cliff.

The competitive frame

No approved drug for chronic cough tied to IPF or other interstitial lung diseases exists, so Trevi is not fighting incumbent therapeutics — it is creating a category. That is both liberation and risk. The liberation is obvious: if Haduvio works and gets approved, it can command a meaningful price and face little direct competition in the first years of launch. The risk is that if development stalls, there is no fallback: this is a single-pipeline company betting everything on one molecule in one indication.

Rivals are sparse but not nonexistent. Vertex Pharmaceuticals, Roche, and others have cough assets in development. Theravance, historically strong in respiratory, is focused more on COPD and asthma. The window for Trevi to establish Haduvio as the first-mover cough treatment in IPF is now — before other players mount competing programs — but that window will close if trials slip or data disappoint.

The burn and the capital question

Trevi is pre-revenue and burning cash to fund trials and operations. The company’s path to sustainability depends entirely on successful Phase 3 results leading to approval, commercial launch, and eventual profitability. That is years away. How long the company can operate on its current balance sheet, how much dilution shareholders will face if capital is needed, and whether the company can partner or out-license Haduvio to larger players (to raise cash and derisking ) are all open. If trials slow or if the company wants to explore additional indications (like non-IPF interstitial lung disease, which Trevi is considering), cash needs rise.

The advantage of a focused pipeline is simplicity. The company does not have to manage ten programs at different stages; it can concentrate resources on making Haduvio work. The disadvantage is fragility. If something goes wrong with Haduvio — unexpected toxicity, failure to meet efficacy endpoints, manufacturing issues — there is no other program to pivot to. The company’s bet is an all-or-nothing one, and the next Phase 3 readouts will determine whether the bet was vindicated or misplaced.

The investor calculus

Trevi trades on the probability and timing of successful Phase 3 results. The clinical evidence so far is encouraging, but Phase 2 efficacy does not guarantee Phase 3 success. Enrollment timelines, unexpected safety signals, or competitor announcements could all reshape the stock. For investors, the key metric is expected cash runway and the baseline probability of Phase 3 success in each indication. The company’s quarterly earnings reports discuss cash position and upcoming trial milestones. Any earnings miss or trial delay will be read as a setback; any data acceleration or partnering announcement will be read as a de-risking.

Cough caused by lung disease is understudied and undertreated. Trevi’s bet that nalbuphine can fill this gap is neither fanciful nor assured. The next two to three years of clinical data will determine whether the company has identified a genuine therapeutic opportunity or a clinical dead-end wearing a sympathetic indication. For now, the company moves forward on the strength of Phase 2 signals and the absence of any better option for these patients.